Deficiencies in HR, such as BRCA1/2 mutations or altered Rad51 expression, are known contributors to genomic instability and are associated with both increased sensitivity to PARP inhibitors and resistance to certain chemotherapeutic agents in NSCLC [18]. The gene discussed is RAD51; the disease is non-small cell lung carcinoma.